Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Key Points

• Jefferies Financial Group has increased its price target for Regeneron Pharmaceuticals from $813.00 to $831.00, indicating a potential upside of 41.41% from its previous close.
• The stock currently has a Moderate Buy rating according to analysts, with an average target price of $829.71 and a mix of ratings with seventeen being "Buy" and three as "Strong Buy".
• Regeneron reported impressive quarterly earnings, with $12.89 earnings per share, significantly surpassing the consensus estimate of $8.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target upped by stock analysts at Jefferies Financial Group from $813.00 to $831.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Financial Group's target price would suggest a potential upside of 41.41% from the stock's previous close.

Several other research analysts have also recently weighed in on REGN. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. The Goldman Sachs Group cut their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Finally, Citigroup restated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $829.71.

Regeneron Pharmaceuticals Stock Up 2.7%

Shares of REGN stock opened at $587.65 on Wednesday. The stock has a 50 day moving average of $553.05 and a 200 day moving average of $589.45. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $62.28 billion, a P/E ratio of 14.81, a P/E/G ratio of 1.91 and a beta of 0.33. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $11.56 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the business. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management increased its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.